Google
Trusted Resources: News & Events
Latest announcements and gatherings
Phase 3 Trial Recruiting to Test Rivipansel for Vaso-Occlusive Crisis in SCD
GlycoMimetics, in collaboration with Pfizer, is now enrolling participants for a Phase 3 clinical trial to test the effectiveness and safety of the drug candidate rivipansel (GMI-1070) for the treatment of vaso-occlusive crisis (VOC) in hospitalized patients with sickle cell disease (SCD).
“We can report that the Phase 3 program to evaluate rivipansel for vaso-occlusive sickle cell crisis, according to our partner Pfizer, remains on track for completion in the second half of 2018,” Rachel King, CEO of GlycoMimetics, said in a press release.
+myBinderRelated Content
-
Hospital Playroom Transformed Into Romantic Restaurant For Parents Of Kids With Bone Marrow TransplantsIt was Valentine’s Day with a lot of h...
-
Pain and opioid use after reversal of sickle cell disease following hematopoietic stem cell transplantPain is the most common symptom of sickl...
-
6th Annual Chicago Sickle Cell SummitDate & Time Sep 28, 2023 11:00 AM...
-
Health disparity in hematopoietic cell transplantation for sickle cell disease: Analyzing the association of insuran...The impact of racial and socioeconomic s...
-
Safety and early hints of benefit seen in phase 1b trial of PF-04447943Sickle cell disease (SCD) patients were ...
-
Let Your Light Shine: Yoga & MeditationPiedmont Health Services and Sickle Cell...
-
CIRM and NHLBI Collaborating to Fund Cell and Gene Therapies for Sickle Cell DiseaseThe California Institute for Regenerativ...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.